Ozempic vs Wegovy: One Drug, Two Licences?

They contain the same active ingredient, yet they aren't interchangeable. Here's why the UK licenses semaglutide under two different names.

Key takeaways

• Ozempic and Wegovy are both semaglutide — the same active drug.
• Ozempic is licensed for type 2 diabetes; Wegovy for weight management.
• A licence defines what a medicine is approved and studied for.
• Which one is appropriate is a prescriber's decision.

It's one of the most common points of confusion in the whole GLP-1 story: Ozempic and Wegovy are the same drug, so why two names?

Both are semaglutide. The difference isn't the molecule — it's the licence. Think of it a little like the same engine fitted to two different vehicles, each tuned and approved for a different journey.

What a 'licence' actually means

In the UK, the MHRA grants a marketing authorisation — a licence — that specifies exactly what a medicine is approved to treat, and for whom. Ozempic's licence centres on type 2 diabetes; Wegovy's centres on weight management.

A licence is built on the evidence a manufacturer submits. Studies are run for a particular purpose, in a particular group of people, and the licence reflects that work. So when two brands share an active ingredient but carry different licences, it usually means each was studied and approved for its own specific job.

The two are also typically presented as different products — for instance with their own dose steps and pens — rather than being one item with two stickers. That's part of why a pharmacist can't simply swap one for the other.

Why it matters to you

• They're prescribed through different routes and for different reasons.
• Using one 'off-label' to do the other's job is a clinical decision, not a shortcut to make alone.
• Supply pressures have at times meant Ozempic is protected for people with diabetes — see Shortages and Supply.

In everyday terms, this is why you can't reliably treat the two names as interchangeable, even though chemically they're siblings. The brand a prescriber reaches for depends on what they're treating and which licence fits your situation — not on which name happens to be more famous.

Where the confusion comes from

Ozempic became a household word first, so its name often gets used as shorthand for the whole idea of a 'weight-loss jab'. That's understandable, but it's slightly back-to-front: Ozempic's licence is the diabetes one, and the weight-management licence for the same drug sits under a different name. The medicines themselves haven't changed; the everyday language just hasn't caught up.

It's worth saying clearly that neither is 'the strong one' or 'the weak one'. They're the same molecule, so the differences come down to which use each has been licensed and dosed for — not to one being a better or more powerful medicine than the other. Keeping that in mind stops a more famous name from quietly doing the deciding for you.

The honest summary Same drug, different job. A prescriber matches the licensed product to your situation — not to the brand name you happen to have heard of.

What this means for you

If you've heard one name and assumed it does everything, you're in good company — but the practical takeaway is simple. Focus less on the brand and more on the goal you'd be treating, and let a qualified prescriber map that goal to the right licensed product. That's the safest, most honest route through the confusion.

For the bigger picture of the whole family, see How GLP-1 Medicines Work Inside the Body, and for the broader set of misunderstandings, Common GLP-1 Myths, Cleared Up.

Sources

• MHRA
• NICE
• manufacturer prescribing information